JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB23513

Anti-PKC alpha (phospho S657 + Y658) antibody

4

(6 Reviews)

|

(24 Publications)

Rabbit Polyclonal KPCA phospho S657 + Y658 antibody. Suitable for ICC, WB and reacts with Rat samples. Cited in 24 publications. Immunogen corresponding to Synthetic Peptide within Human PRKCA phospho S657 + Y658.

View Alternative Names

PKCA, PRKACA, PRKCA, Protein kinase C alpha type, PKC-A, PKC-alpha

3 Images
Immunocytochemistry - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)
  • ICC

PubMed

Immunocytochemistry - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)

Immunofluorescence analysis of S2-013 cells, staining PKC alpha (phospho S657 + Y658) with ab23513.

Cells were fixed with paraformaldehyde, permeabilized with 0.1% Triton X-100, and blocked with blocking solution (3% BSA/PBS). Cells were incubated with primary antibody for 1 hour. An AlexaFluor®488-conjugated anti-rabbit IgG was used as the secondary antibody.

Image from Taniuchi K et al., PLoS One. 2012;7(4):e35674. Epub 2012 Apr 19. Fig 8.; doi:10.1371/journal.pone.0035674; April 19, 2012, PLoS ONE 7(4): e35674.

Immunocytochemistry - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)
  • ICC

Supplier Data

Immunocytochemistry - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)

Immunocytochemical labeling of PKC phosphorylation in aldehyde-fixed and NP-40-permeabilized NGF-differentiated PC12 cells. The cells were labeled with rabbit polyclonal anti-PKCα (Ser-657/Tyr-658) (PP1091) antibody in the absence (Left) or presence (Right) of blocking peptide (PX1095). The antibody was detected using appropriate secondary antibody conjugated to DyLight® 594

Western blot - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)
  • WB

Supplier Data

Western blot - Anti-PKC alpha (phospho S657 + Y658) antibody (AB23513)

Western blot analysis of immunoprecipitates from neonatal rat brain lysate using anti-PKCα antibody. Control and alkaline phosphatase treated precipitates were probed with anti-PKCα (Central region) or anti-phospho-PKCα (Ser-657/Tyr-658).

All lanes:

Western blot - Anti-PKC alpha (phospho S657 + Y658) antibody (ab23513)

Predicted band size: 76 kDa

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Rat

Applications

WB, ICC

applications

Immunogen

Synthetic Peptide within Human PRKCA phospho S657 + Y658. The exact immunogen used to generate this antibody is proprietary information.

P17252

Specificity

ab23513 detected PKC alpha and PKC beta I, but not other PKC isoforms in rat brain lysate.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICC" : {"fullname" : "Immunocytochemistry", "shortname":"ICC"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Rat": { "ICC-species-checked": "testedAndGuaranteed", "ICC-species-dilution-info": "", "ICC-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>" } } }

Product details

We do not have concentration information for this antibody. It is optimized to work at the dilutions stated on the datasheet.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification
Storage buffer
Preservative: 0.05% Sodium azide Constituents: PBS, 50% Glycerol (glycerin, glycerine), 0.1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PKC alpha known as Protein Kinase C alpha is a serine/threonine-specific protein kinase involved in various cellular processes. The molecular mass of PKC alpha is approximately 80 kDa. Alternately called PKCA or PRKC alpha it is expressed in many tissues with high expression in the brain heart and lungs. PKC alpha plays a role in signal transduction by phosphorylating serine and threonine residues on target proteins.
Biological function summary

PKC alpha regulates cellular functions including proliferation differentiation and apoptosis. It often acts as part of a larger protein complex modulating various biological responses by interacting with substrates and co-factors. Its activity is dependent on calcium ions and diacylglycerol emphasizing its role in calcium and lipid signaling pathways.

Pathways

PKC alpha plays a vital role in the MAPK/ERK pathway and the PI3K/AKT pathway which are critical for the cellular stress response and growth regulation. PKC alpha interacts with several proteins in these pathways including RAF1 and AKT1 facilitating signal transmission that influences cell fate decisions.

PKC alpha has been implicated in cancer and cardiac hypertrophy. In cancers aberrant PKC alpha signaling is linked to increased cell proliferation and survival. In cardiac hypertrophy it is associated with abnormal heart growth due to impaired signaling involving AKT1 and GSK3B. These connections highlight PKC alpha's influence in pathological as well as physiological conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42 (PubMed : 28028151). Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-52' facilitating its ubiquitination and proteasomal degradation (By similarity). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed : 25313067). Phosphorylates and activates LRRK1, which phosphorylates RAB proteins involved in intracellular trafficking (PubMed : 36040231).
See full target information PRKCA phospho S657 + Y658

Publications (24)

Recent publications for all applications. Explore the full list and refine your search

Brazilian journal of anesthesiology (Elsevier) 74:844501 PubMed38583586

2024

Apelin-13 reverses bupivacaine-induced cardiotoxicity: an experimental study.

Applications

Unspecified application

Species

Unspecified reactive species

Xixi Cai,Le Liu,Fangfang Xia,Thomas J Papadimos,Quanguang Wang

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 36:e22273 PubMed35349200

2022

Protein Kinase C α and β compensate for each other to promote stem cell factor-mediated KIT phosphorylation, mast cell viability and proliferation.

Applications

Unspecified application

Species

Unspecified reactive species

Lakshminarayan Reddy Teegala,Yasmine Elshoweikh,Ravindra Gudneppanavar,Sathwika Thodeti,Sabita Pokhrel,Erik Southard,Charles K Thodeti,Sailaja Paruchuri

International journal of molecular sciences 22: PubMed34769018

2021

NLRP3 Inflammasome Blocking as a Potential Treatment of Central Insulin Resistance in Early-Stage Alzheimer's Disease.

Applications

Unspecified application

Species

Unspecified reactive species

Yulia K Komleva,Ilia V Potapenko,Olga L Lopatina,Yana V Gorina,Anatoly Chernykh,Elena D Khilazheva,Alla B Salmina,Anton N Shuvaev

Oncology letters 22:832 PubMed34712357

2021

Delphinidin induces cell cycle arrest and apoptosis in HER-2 positive breast cancer cell lines by regulating the NF-κB and MAPK signaling pathways.

Applications

Unspecified application

Species

Unspecified reactive species

Ailin Wu,Yanfeng Zhu,Bin Han,Jiayuan Peng,Xiaomin Deng,Wei Chen,Jingchang Du,Yu Ou,Xiaoli Peng,Xiaoping Yu

FEBS open bio 11:75-84 PubMed33125833

2020

Aquaporin 1 mediates early responses to osmotic stimuli in endothelial cells via the calmodulin pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yong Jiang,Chengqi Wang,Rui Ma,Ying Zhao,Xinyue Ma,Jiaxin Wan,Chunxiang Li,Fanghao Chen,Fang Fang,Mingguang Li

Haematologica : PubMed32855276

2020

Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.

Applications

Unspecified application

Species

Unspecified reactive species

Simon Hultmark,Aurélie Baudet,Ludwig Schmiderer,Pavan Prabhala,Sara Palma-Tortosa,Carl Sandén,Thoas Fioretos,Rajkumar Sasidharan,Christer Larsson,Sören Lehmann,Gunnar Juliusson,Fredrik Ek,Mattias Magnusson

Photodiagnosis and photodynamic therapy 31:101813 PubMed32442674

2020

Searching for combination therapy by clustering methods: Stimulation of PKC in Golgi apparatus combined with hypericin induced PDT.

Applications

Unspecified application

Species

Unspecified reactive species

Lenka Lenkavska,Silvia Tomkova,Denis Horvath,Veronika Huntosova

Frontiers in pharmacology 10:1589 PubMed32116659

2020

Five Constituents in L. Attenuate Palmitic Acid-Induced Hepatocyte Injury Inhibiting the Protein Kinase C-α/Nicotinamide-Adenine Dinucleotide Phosphate Oxidase Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Lishan Zhou,Jianqiao Tang,Xuan Yang,Hui Dong,Xiaoli Xiong,Juan Huang,Linli Zhang,Huan Qin,Suqi Yan

Scientific reports 9:11046 PubMed31363142

2019

Inhibition of the Akt1-mTORC1 Axis Alters Venous Remodeling to Improve Arteriovenous Fistula Patency.

Applications

Unspecified application

Species

Unspecified reactive species

Xiangjiang Guo,Arash Fereydooni,Toshihiko Isaji,Jolanta Gorecka,Shirley Liu,Haidi Hu,Shun Ono,Michelle Alozie,Shin Rong Lee,Ryosuke Taniguchi,Bogdan Yatsula,Naiem Nassiri,Lan Zhang,Alan Dardik

Frontiers in immunology 10:1039 PubMed31134090

2019

The Antidiabetic and Antinephritic Activities of (An Albino Mutant Strain) via Modulation of Oxidative Stress in the db/db Mice.

Applications

Unspecified application

Species

Unspecified reactive species

Di Wang,Xue Jiang,Shanshan Teng,Yaqin Zhang,Yang Liu,Xiao Li,Yu Li
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com